Article: Neurocrine Reports Positive Data on Insomnia Drug (Biotech).(indiplon from Neurocrine Biosciences Inc.)(Brief Article)

Article: Neurocrine Biosciences, Inc. Reports Positive Phase ...
PR Newswire;  November 29, 1999 ;     700+ words ...SAN DIEGO, Nov. 29 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a Phase II clinical trial demonstrating that NBI-34060 is a robust sedative hypnotic as demonstrated by a highly statistically significant and clinically relevant effect in inducing sleep

Article: Neurocrine Biosciences, Inc. Reports Positive Phase ...
PR Newswire;  November 30, 1999 ;     700+ words ...SAN DIEGO, Nov. 30 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from a Phase II clinical trial demonstrating that NBI-34060 is a robust sedative hypnotic as demonstrated by a highly statistically significant and clinically relevant effect in inducing sleep

Article: Guangzhou Xingqun Pharma's TCM insomnia drug to hit ...
China Business News;  June 13, 2007 ;     698 words ... ... Guangzhou Xingqun Pharma's TCM insomnia drug to hit annual sales of $13 mln ... Ye will become the second TCM insomnia drug, behind Jilin AoDong Medicine Industry Group Co. Ltd's TCM insomnia drug to reach annual sales revenue ...

Article: In 2005, Sepracors New Insomnia Drug Lunesta ...
M2 Presswire;  April 27, 2007 ;     700+ words ... ... and Markets: In 2005, Sepracors New Insomnia Drug Lunesta Accounted For the Greatest ... 27042007 In 2005, Sepracor's New Insomnia Drug Lunesta Accounted For the Greatest ... In 2005, Sepracor's new insomnia drug Lunesta (eszopiclone) accounted for ...

Article: Somaxon makes big entry into competitive arena: insomnia ...
San Diego Business Journal;  June 20, 2005 ;     700+ words ... ... test Silenor, an experimental insomnia drug it licensed from Dr. Neil Kavey ... firm, which has a promising insomnia drug started, people thought the ... much smaller." Neurocrine's insomnia drug, indiplon, is up for FDA approval ...

Article: Analysts predict sweet dreams lie ahead for Neurocrine. ...
San Diego Business Journal;  March 18, 2002 ;     700+ words ... ... alone in his belief that Neurocrine's insomnia drug candidate could rival market leader ... Neurocrine's CFO. Besides its lead insomnia drug, Neurocrine wants to develop drug ... about $200 million to develop the insomnia drug alone. As of December, Neurocrine ...

Article: Insomnia: drug makers see 'huge, numbers'.
Providence Journal (Providence, RI);  January 30, 2005 ;     700+ words ... ... made by Sepracor of Marlborough, Mass., is the first insomnia drug approved by the federal Food and Drug Administration for ... accounts for about 75 percent of the $2-billion U.S. insomnia drug market. According to Merrill Lynch, Sepracor will sell ...